Alumis Earnings Call Transcripts
Fiscal Year 2026
-
Envudeucitinib’s phase III ONWARD trials showed robust skin clearance, rapid itch reduction, and strong quality-of-life improvements in moderate to severe plaque psoriasis, with a favorable safety profile through 24 weeks. Its efficacy, especially in itch relief, positions it as a leading oral option, with further studies planned.
-
Envudeucitinib showed top-tier efficacy and rapid onset in phase III psoriasis trials, with long-term data and NDA filing expected in the second half of the year. The company is expanding its TYK2 franchise into lupus and other indications, with a focus on strategic partnerships and a once-daily formulation in development.
-
Positive Phase 3 data for envudeucitinib in psoriasis showed strong efficacy and safety, with NDA submission planned for the second half of the year. SLE pivotal trial data is expected in Q3, and the company is evaluating broader TYK2 franchise opportunities and potential partnerships.
-
Phase III data for envudeucitinib in psoriasis showed strong efficacy and safety, with NDA filing planned for the second half of the year. The company is preparing for commercial launch and expanding its pipeline into SLE, MS, and other autoimmune indications, supported by a strong cash position.
-
Envudeucitinib achieved highly significant efficacy and safety in phase III psoriasis trials, with rapid and deep skin clearance, strong patient-reported outcomes, and a favorable safety profile. The results support its potential as a leading oral therapy, with broader applications in immune-mediated diseases and an NDA filing planned for late 2026.
Fiscal Year 2025
-
Multiple late-stage readouts for oral TYK2 inhibitor Envudeucitinib in psoriasis and lupus are expected in 2026, with strong efficacy and safety data supporting its potential. Strategic plans include partnering the lead asset and advancing additional pipeline candidates, supported by a cash runway into 2027.
-
Envutuzitinib is advancing with key phase III psoriasis and phase IIb lupus data expected in 2024, supported by strong safety and efficacy profiles. The company maintains a robust pipeline and financial position, with over $480 million in cash and operational runway into 2027.
-
Alumis is advancing a robust immunology pipeline led by ESK-001, a next-gen TYK2 inhibitor for psoriasis and lupus, with key readouts in 2024. The company is well-funded through 2027, preparing for potential independent commercialization, and exploring additional indications and assets.
-
Lead TIK2 inhibitor Envu is advancing in phase 3 for psoriasis and phase 2 for lupus, with key data readouts expected in early 2025 and late summer 2025, respectively. The company maintains a strong financial position, is expanding its pipeline, and is preparing for global commercialization with a focus on high-efficacy oral therapies and strategic flexibility.
-
The company is advancing precision immunology with lead TYK2 inhibitor programs in psoriasis and lupus, aiming for key readouts in 2024. Differentiation is based on sustained target inhibition and a strong safety profile, with a robust financial position supporting strategic flexibility.
-
Three clinical assets are advancing, with phase III psoriasis and pivotal lupus trial readouts expected in 2024. The lead TYK2 inhibitor shows strong efficacy and safety, aiming for a 2026 filing. Market strategy focuses on oral preference and global partnerships, with $486M in cash runway into 2027.
-
A robust immunology pipeline is advancing with key phase III and pivotal trials in psoriasis and lupus, supported by strong genetic rationale and a differentiated TYK2 inhibitor. Significant market opportunities exist for oral therapies, and the company is well-funded with a cash runway into 2027.
-
Alumis is advancing its TYK2 inhibitor ESK-001 in psoriasis and lupus, with strong efficacy and safety data positioning it as a competitive oral therapy. Accelerated timelines, a broadening pipeline, and ongoing work on new formulations and indications highlight a year of significant execution.
-
Two advanced TYK2 assets show strong efficacy and safety in psoriasis, lupus, and MS, with pivotal readouts expected next year. The recent Acelyrin merger adds capital and a new asset, extending the financial runway into 2027 and expanding the pipeline.
-
The merger creates a well-capitalized immunology company with a diversified late-stage pipeline and extended cash runway into 2027. Strategic synergies include operational efficiencies and a focus on capital-efficient development, especially for lonigutamab in thyroid eye disease.
Fiscal Year 2024
-
A precision immunology company is advancing a selective TYK2 inhibitor in phase III for psoriasis and pivotal phase II for lupus, aiming for high efficacy and safety. Global phase III trials are enrolling, with data expected by mid-2026, and a strong cash position supports ongoing development.
-
A precision immunology company is advancing two TYK2 inhibitors: ESK-001 in phase III for psoriasis and phase IIb for lupus, and A-005 in phase I for MS, with strong biomarker and efficacy data. Over $440M in cash supports key readouts into 2026.